Acute liver failure associated with lamotrigine in children with epilepsy: A report of two cases and thoughts on pharmacogenomics

Jie Deng a,1, Zheng-ran Fu b,1, Long Wang c, Jun Liu d, Chun-hong Chen a, Fang Fang a, Xiao-ling Wang b,a

a Department of Neurology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China
b Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China
c Department of Emergency, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China
d Pediatric Intensive Care Unit, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China

Abstract

Pediatric acute liver failure (PALF) is a rare and life-threatening clinical syndrome for which drug-induced liver injury is a cause. Lamotrigine (LTG) is generally a safe and effective antiseizure medication, and PALF related to LTG has rarely been reported. Here, we describe two cases of PALF associated with LTG in children with epilepsy. In both patients, LTG was used in combination with valproic acid at an initial dose exceeding the recommended dose, which increased the risk of adverse reactions. In addition, single nucleotide polymorphisms of genes associated with the pharmacokinetics and pharmacodynamics of LTG were selected for pharmacogenomic testing. However, the results revealed that genotypes of the patients had variable effects on the serum concentration and therapeutic responsiveness of LTG and therefore did not explain the clinical manifestations well. The findings of this case report caution clinicians to be aware of the risk of liver failure when using antiseizure medication in polytherapy, especially LTG in combination with valproic acid. Further pharmacogenomic studies are needed to help improve the efficacy and safety of epilepsy treatment in the future.

Introduction

Pediatric acute liver failure (PALF) is a rapidly progressive clinical syndrome in which children without a history of liver disease suddenly develop liver function impairment and more than half have hepatic encephalopathy, which can be life-threatening [1]. In the United States, approximately 10%–15% of liver transplantsations in children are due to PALF, which must be recognized and treated promptly [2]. The etiologies of PALF are classified as infectious, immunologic, metabolic, or toxin or drug-related, while more than half have no identifiable etiology [3].

Lamotrigine (LTG) belongs to the sodium channel blocking class of antiseizure medications (ASMs). LTG is widely used in patients with epilepsy and is generally safe and effective. A rare adverse effect of LTG is hepatic injury, and PALF associated with LTG has been even more rarely reported. Here, we describe two cases of PALF after LTG administration in children with epilepsy in the hope of drawing attention to the safety of the application of ASM in children.

In addition, single nucleotide polymorphisms (SNPs) in certain genes have been reported to be associated with LTG pharmacokinetics and pharmacodynamics. We selected several of these SNPs for which data from Chinese population studies were available, and we performed pharmacogenomic testing to initially explore their possible role in PALF occurrence.

Case presentation

Patient 1, a 13-year-old girl, developed seizures at the age of 10 years, which were focal to bilateral tonic-clonic seizures. In the most recent year, she was on valproate sodium (VPA) 0.4 g twice daily and clonazepam 8 mg/day, with a seizure frequency of once a week. Twenty-four days before admission, the local clinic added LTG 25 mg twice daily (2 mg/kg/day) for combination therapy. Ten days after taking LTG, she developed a fever with a maximum temperature of 40 °C. Three days later, a rash appeared and...
spread rapidly over her body, followed by a progressive yellowish staining of her skin. Her mental state gradually deteriorated, and her seizures increased to 1–2 times/day. She had an uneventful perinatal period, delayed speech development, and no history of allergies. Her father, older brother and sister all suffered from childhood-onset drug-resistant epilepsy and epileptic encephalopathy. Furthermore, the brother died of epilepsy at the age of 15 years (Fig. 1A).

Physical examination found that the girl was lethargic, with generalized skin and scleral jaundice and a patchy, dark red rash (Fig. 1B) but no hepatomegaly or splenomegaly. Laboratory tests results were as follows: total bilirubin, 481 μmol/L (upper limit of normal, ULN = 20.5 μmol/L); direct bilirubin, 369 μmol/L (ULN = 3.42 μmol/L); alanine aminotransferase (ALT), 73.5 U/L (ULN = 29 U/L); gamma-glutamyltransferase (γGT), 920 u/L (ULN = 26 U/L); prothrombin time, 56.6 s (reference 9.4–12.5 s); activated thromboplastin time, 76.3 s (reference 25.1–38.4 s); and international normalized ratio, 4.96. The serum LTG concentration was 10.6 μg/ml 60 h after the last dose (Table 1). The results of tests for hepatitis virus were negative. Homocysteine, ceruloplasmin and alpha-fetoprotein were normal. Abdominal ultrasound showed elevated hepatic elasticity, deflation and wall thickening of the gallbladder. Abdominal CT indicated fullness of the liver and spleen with normal CT values (Fig. 1D). Cranial CT showed a deepening of the cerebral and cerebellar sulci (Fig. 1C). The results of subsequent pharmacogenomic testing are shown in Table 1.

The girl was diagnosed with epilepsy, acute liver failure, and stage II hepatic encephalopathy. LTG and VPA were immediately discontinued and replaced with levetiracetam. She received intravenous reductive glutathione and ornithine aspartate to protect hepatic function in combination with oral ursodeoxycholic acid to promote bilirubin excretion. In addition, she was administered vitamin K1 intramuscularly and fresh frozen plasma infusion to improve coagulation function. However, the parents abandoned the treatment 2 days later due to financial difficulties, and the girl died a few days later.

Patient 2, a 3-year-7-month-old boy, presented with seizures at 6 months old, which were focal clonic seizures, mostly during fever, with recurrent episodes of status epilepticus. The initial administration of oxcarbazepine aggravated the seizures, therefore oxcarbazepine was changed to a combination of VPA, clonazepam, levetiracetam and topiramate. At the age of 3 years, a suspected epileptogenic focus was resected at a local hospital. However, he still had 1–2 episodes of status epilepticus per month. Two weeks before admission, LTG 12.5 mg once daily (0.7 mg/kg/day) was added by a local clinic. After taking LTG for one week, the boy developed a fever with a maximum temperature of 39.5 °C. Two days later, elevated transaminases were detected, so LTG was discontinued, but he developed impaired consciousness and frequent seizures with vomiting and diarrhea. He had mild mental and motor retardation, no history of allergies, and no relevant family history (Fig. 2A).

Physical examination found a Glasgow coma score of 8 and no jaundice or rash but hepatomegaly and splenomegaly. Laboratory tests results were as follows: ALT, 7267.7 U/L (ULN = 30 U/L); aspartate aminotransferase, 4834.7 U/L (ULN = 45 U/L); γGT, 296
U/L (ULN = 19 U/L); and ammonia, 143 µmol/L (ULN = 74 µmol/L) (Table 1). There was no specific abnormality in blood or urine screening for congenital metabolic disorders, and the results of tests for hepatotropic viruses were negative. The serum concentration of VPA was 83.75 µg/ml. Abdominal ultrasound demonstrated an enlarged liver with rough parenchymal echogenicity and cholecys-tic bed edema. Brain MRI showed postoperative gliosis around the resected lesion in the left frontal lobe (Fig. 2C). Electroencephalo-gram recorded slowed background activity and epileptiform dis-charges predominantly in the right temporal and frontal leads (Fig. 2D). A gene panel testing for epilepsy identified a de novo heterozygous variant c.971A > C (p.His324Pro) of SCN1A, which was interpreted as likely pathogenic (Fig. 2B). The results of phar-macogenomic testing are shown in Table 1.

The boy was diagnosed with epilepsy (specifically, Dravet syn-drome), acute liver failure, and stage III hepatic encephalopathy. Respiratory support was provided by nasal continuous positive air-way pressure. He received intravenous reductive glutathione and ornithine aspartate, combined with oral glucuronolactone and bicyclol to protect hepatic function; intravenous arginine to reduce ammonia; and intravenous prothrombin complex to improve coag-ulation function. All ASMs were discontinued and replaced with intravenous pumped midazolam. After 2 weeks of treatment, his liver function returned to normal. The ASMs were switched to VPA, levetiracetam, topiramate and nitrazepam, after which the seizures decreased. The boy has been followed up for 2.5 years to date and has had one seizure every 1–2 months, with cluster attacks during fever.

According to the Roussel Uclaf causality assessment method (RUCAM), the scores of the two patients were 5 and 8, so that the degree of causality between hepatotoxicity and LTG was possi-bile and probable, respectively (Table 2). However, the score for case 1 was low due to the lack of recheck data, which did not match her severity and prognosis. In conclusion, we suggest that these two cases of PALF were likely to be drug-induced liver injury (DILI) associated with LTG.

### Discussion

Liver failure induced by LTG is rare and life-threatening. In 1995, Makin et al. reported the first case [4], and Arnon et al. first reported a pediatric case in 1998 [5]. From 2004 to June 2022, the Food and Drug Administration Adverse Event Reporting System recorded 211 cases of LTG-related liver failure, with 59 (28.0 %) deaths, of which 39 (18.5 %) of the patients were younger than 18 years of age and 2 (5.1 %) died. The mechanism of LTG-related liver failure is not well understood and is currently considered to

### Table 1

| Case 1 | Case 2 |
|--------|--------|
| **Primary disease** | Epilepsy | Epilepsy – Dravet Syndrome |
| **Age/Sex** | 13y /F | 3y7m /M |
| **Dose of LTG** | 2 mg/kg/day | 0.69 mg/kg/day |
| **Concurrent medications** | VPA, CZP | VPA, LEV, CZP, TPM |

**Laboratory tests**

| | Case 1 | Case 2 |
|----------------|-------|-------|
| **Worst liver function abnormality** | AST 111.9 U/L | AST 4834.7 U/L |
| **ALP 846 U/L** | ALP 374 U/L |
| **ALT 73.5 U/L** | ALP 7267.7 U/L |
| **γGT 920 U/L** | γGT 296 U/L |
| **TBil 481 µmol/L** | TBil 22.77 µmol/L |
| **DBil 369 µmol/L** | DBil 14.42 µmol/L |
| **TBA 119 µmol/L** | TBA 119 µmol/L |
| **TRF 119 µmol/L** | TRF 119 µmol/L |

**Coagulation function**

| | Case 1 | Case 2 |
|----------------|-------|-------|
| **PT 56.6 s** | PT 23 s |
| **INR 4.96** | INR 2.03 |
| **FIB 2.42 g/L** | FIB 1.18 g/L |
| **D-Dimer 0.077 mg/L** | D-Dimer 2.67 mg/L |

**Serum concentration of LTG**

| | Case 1 | Case 2 |
|----------------|-------|-------|
| **LTG pharmacokinetics** | 10.6 µg/ml (50 h after last dose) | 0.2 µg/ml (1 week after last dose) |
| **LTG pharmacodynamics** | UGT1A4 rs2011425 TT | UGT1A4 rs2011425 TT |
| **SCN2A** | rs2304016 AG |
| **SLC22A1** | rs628031 GG |
| **ABCG2** | rs3114020 CC |
| **UGT2B7** | rs7668258 CT |

**Hepatomegaly**

| | Case 1 | Case 2 |
|----------------|-------|-------|
| **Jaundice** | + | – |
| **Fever** | + | + |

**Laboratory tests**

| | Case 1 | Case 2 |
|----------------|-------|-------|
| **Laboratory tests** | AST 111.9 U/L | AST 4834.7 U/L |
| **ALT 73.5 U/L** | ALT 7267.7 U/L |
| **γGT 920 U/L** | γGT 296 U/L |
| **TBil 481 µmol/L** | TBil 22.77 µmol/L |
| **DBil 369 µmol/L** | DBil 14.42 µmol/L |
| **TBA 119 µmol/L** | TBA 119 µmol/L |
| **TRF 119 µmol/L** | TRF 119 µmol/L |
| **ALP 846 U/L** | ALP 374 U/L |
| **ALT 73.5 U/L** | ALT 7267.7 U/L |
| **γGT 920 U/L** | γGT 296 U/L |
| **TBil 481 µmol/L** | TBil 22.77 µmol/L |
| **DBil 369 µmol/L** | DBil 14.42 µmol/L |
| **TBA 119 µmol/L** | TBA 119 µmol/L |
| **TRF 119 µmol/L** | TRF 119 µmol/L |

**Coagulation function**

| | Case 1 | Case 2 |
|----------------|-------|-------|
| **PT 56.6 s** | PT 23 s |
| **INR 4.96** | INR 2.03 |
| **FIB 2.42 g/L** | FIB 1.18 g/L |
| **D-Dimer 0.077 mg/L** | D-Dimer 2.67 mg/L |

**Complete blood count**

| | Case 1 | Case 2 |
|----------------|-------|-------|
| **WBC 3.53 × 10^9/L** | WBC 3.63 × 10^9/L |
| **Lym 29.7 %** | Lym 12.8 % |
| **Eo 0.3 %** | Eo 0 % |
| **Hb 87 g/L** | Hb 123 g/L |
| **PLT 65 × 10^9/L** | PLT 79 × 10^9/L |

**Serum concentration of LTG**

| | Case 1 | Case 2 |
|----------------|-------|-------|
| **Serum concentration of LTG** | 10.6 µg/ml (50 h after last dose) | 0.2 µg/ml (1 week after last dose) |

**Outcome**

| | Case 1 | Case 2 |
|----------------|-------|-------|
| **Outcome** | Died | Recovered |
be idiosyncratic DILI [6]. Active drug metabolites, genetic susceptibility and environmental factors are involved in the development of DILI, with complex interactions among them [7].

Higher dose, rapid titration, and combination with VPA have been linked with higher incidence of LTG hepatotoxicity [8]. When used in combination with VPA, the blood concentration of LTG is approximately doubled, and the half-life is prolonged more than twice [9]. In both cases, VPA had been taken for more than 2 years before the addition of LTG. In patients receiving VPA, the starting dose of LTG must be less than half of that without combined VPA, and the recom-

**Table 2**

RUCAM for the hepatotoxicity with LTG of the two cases.

| Patterns of hepatotoxicity | Case 1: Cholestatic | Case 2: Hepatocellular |
|---------------------------|---------------------|------------------------|
| 1. Time to onset from the beginning of the drug | 5–90 days | 5–90 days |
| 2. Course of ALP/ALT after cessation of the drug | No information | Decrease ≥ 50% within 8 days |
| 3. Risk factors | | |
| Alcohol use | 0 | 0 |
| Age < 55 years | 0 | 0 |
| 4. Concomitant use of drug | | |
| Concomitant drug with incompatible time to onset | 0 | 0 |
| 5. Search for alternative causes | | |
| Group I: HAV, HBV, HCV, HEV, Hepatobiliary sonography/CT, Alcoholism, Acute recent hypotension history | | |
| Group II: CMV, EBV, HSV, Complications of underlying disease | | |
| Evaluation of groups I and II: The 7 causes of group I ruled out | 1 | 1 |
| 6. Previous hepatotoxicity of the drug | | |
| Reaction labelled in the product characteristics | 2 | 2 |
| 7. Response to unintentional reexposure | | |
| Other situations | 0 | 0 |
| Total score | 5 | 8 |
| Causal relationship | Possible | Probable |

ALP, alkaline phosphatase; ALT, alanine aminotransferase; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HEV, hepatitis E virus; EBV, Epstein-Barr virus; CMV, cytomegalovirus; HSV, herpes simplex virus.

Fig. 2. Case 2. (A) Family pedigree of case 2. (B) Sanger sequencing confirmed a de novo heterozygous variant c.971A > C (p.His324Pro) of the SCN1A gene. (C) Axial, FLAIR brain MRI showed postoperative gliosis around the resected lesion in the left frontal lobe. (D) Electroencephalogram showed interictal epileptiform discharges predominantly in right temporal and frontal leads.
mended initial dose of LTG for children aged 2–12 years is 0.15 mg/kg/day. However, the initial dose in case 1 exceeded the recommended dose by 13.3 times, while in case 2 by 4.6 times, significantly increasing the risk of adverse drug reactions.

With recent advances in pharmacogenomics, genetic factors have been revealed to contribute significantly to the high variability in the response to ASMs across people with epilepsy [10,11]. Individual responses to drugs are associated with variations in a range of gene categories affecting pharmacokinetics and pharmacodynamics [12]. LTG is cleared by the glucuronidation pathway associated with uridine diphosphate glycosyltransferase (UGT). LTG transport is associated with ABCG2, which encodes ATP-binding cassette subfamily G member 2, and SLC22A1, which encodes the solute carrier family 22 member 21. Pharmacogenetic testing for these genes may be useful in assessing individual metabolism of LTG [13]. In addition, certain SNPs of genes encoding voltage-gated sodium channels were suggested to be involved in LTG responsiveness and resistance [14]. Case 1 carried UGT1A4 rs2011425 TT and ABCG2 rs3114020 CC, both of which may lead to a possible increase in serum LTG concentration [15,16], but she also had SLC22A1 rs628031 GG which may decrease the concentration, and UGT2B7 rs7668238 CT, which does not affect the concentration in Han Chinese individuals [17,18]. She carried SCN1A rs2289771 AG, which does not play a significant role in influencing the response to LTG, and SCN2A rs2304016 AG, which may lead to resistance to LTG in the Chinese population [19]. Case 2 carried UGT1A4 rs2011425 TG, which has a frequency of 26% in the Southern Chinese population and has no significant effect on LTG blood concentrations [15,20,21]. The results showed that genotypes of the patients had variable effects on the serum concentration and therapeutic responsiveness of LTG, which could not explain their clinical manifestations well. Therefore, we cannot determine the role of any SNP in causing liver injury at present.

In terms of allergic reaction, as an aromatic ASM, a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in LTG is associated with the HLA-B*15:02 allele [22]. The fact that in both patients HLA-B*15:02 was found to be negative and there was no eosinophilia does not support that their liver failure was a simple allergic reaction.

Conclusion

LTG has the potential to induce life-threatening PALF and requires cautious use. Clinicians should be aware of risk of DILI when a patient is considered for polytherapy, especially including antiseizure medications and improve both efficacy and safety of medications in the future. To date, however, the data from pharmacogenomic studies are relatively limited and preliminary. Large case-cohort studies based on different populations are needed to understand the relationship between genotype and phenotype and to determine the functional impact of the type and frequency of genetic variants.

Ethical statement

The authors confirm that the work was conducted in accordance with the Declaration of Helsinki and the ethical standards of the institutional research committee. The authors have obtained informed consent for publication from the patients’ parents.

Funding

The work was supported by Study of Theoretical Policies and Basic Data on Medication Use in Children (YPT202101).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Squires JE, McKiernan P, Squires RH. Acute liver failure: an update. Clin Liver Dis 2018;22:773–805. https://doi.org/10.1016/j.cld.2018.06.009
[2] Bhatt R, Rao GS. Management of acute liver failure: a pediatric perspective. Curr Pediatr Rep 2018;6:246–57. https://doi.org/10.1007/s40124-018-0174-7
[3] Di Giorgio A, Bartolini E, Calvo PL, Cananzi M, Cirillo F, Delia Corte C, et al. Diagnostic approach to acute liver failure in children: a position paper by the SICENP liver disease working group. Dig Liver Dis 2021;51(S5):545–57. https://doi.org/10.1016/j.dld.2021.03.004
[4] Makin AJ, Fitt S, Williams R, Duncan JS. Fulminant hepatic failure induced by lamotrigine. BMJ 1995;311:202. https://doi.org/10.1136/bmj.311.7000.229d
[5] Arnon R, DeVivo D, Defelec AR, Kazlow PG. Acute hepatic failure in a child treated with lamotrigine. Pediatr Neurol 1998;18(3):251–2. https://doi.org/10.1016/S0887-8994(98)00069-3
[6] Ouellet C, Tremblay L, Marieau D. Fulminant hepatitis induced by Lamotrigine. South Med J 2009;102:82–4. https://doi.org/10.1097/SMJ.0b013e3181387895
[7] Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat Rev Dis Primers 2019;5(1):58. https://doi.org/10.1038/s41572-019-0105-0
[8] Lamotrigine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
[9] Taketomo CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook. 5th edition. Lexi-Comp Inc; 2016.
[10] Stephens C, Andrade RJ. Genetic predisposition to drug-induced liver injury. Clin Liver Dis 2020;24;11–23. https://doi.org/10.1016/j.cld.2019.08.003
[11] Stephens C, Andrade RJ. Genetic risk factors in the development of idiosyncratic drug-induced liver injury. Expert Opin Drug Metab Toxicol 2021;17:153–69. https://doi.org/10.1080/17425255.2021.1854726
[12] Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neurosci Lett 2018;667:27–39. https://doi.org/10.1016/j.neulet.2017.01.014
[13] Mitra-Ghosh T, Callisto SP, Lamba JK, Remmel RP, Birnbaum AK, Barbarino JM, et al. Genetic variation in the UGT1A4 gene is associated with lamotrigine concentrations. Chin J Clin Pharmacol 2015;31:439–42. ,https://doi.org/10.1007/s11810-015-0208-2
[14] Li M, Zhong R, Lu Y, Zhao Q, Li G, Lin W. Association between SCN1A rs2289771, SCN1A rs10188577, SCN2A rs17183814, and SCN2A rs2304016 polymorphisms and responsiveness to antiepileptic drugs: a meta-analysis. Front Neurol 2020;11:.https://doi.org/10.3389/fneur.2020.591828
[15] Chen C-H, Zhang Y-X, Lu R-Y, Jin B, Wang S, Liu Z-R, et al. Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy Res 2016;127:186–90. https://doi.org/10.1016/j.eplepsyres.2016.05.008
[16] Ortega-Vázquez A, Frickle-Galindo I, Dorado P, Jung-Cook H, Martínez-Jáurez IE, Monroe-Jaramillo N, et al. Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. Pharmacogenomics J 2020;20(6):845–56. https://doi.org/10.1007/s12928-020-00547-6
[17] Ortega-Vázquez A, Frickle-Galindo I, Dorado P, Jung-Cook H, Martínez-Jáurez IE, Monroe-Jaramillo N, et al. Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. Pharmacogenomics J 2020;20(6):845–56. https://doi.org/10.1007/s12928-020-00547-6
[18] Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomicas 2008;18 (11):989–98. https://doi.org/10.1097/PCG.0b013e3283117d67
[19] Singkhram N, Towanabut S, Lertkachathorn S, Punyawidhu B. Influence of the UGT2B7 rs1610C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Eur J Clin Pharmacol 2013;69:1285–91. https://doi.org/10.1007/s00228-013-1240-9
[20] Zhou Y, Wang X, Zhou L, Zhang J, Li H, Chen Z, et al. Interethnic differences in UGT1A4 genetic polymorphisms and its effect on lamotrigine trough concentrations. Chin J Clin Pharmacol 2015;31:439–42. https://doi.org/10.13699/j.cnki.1001-6821.2015.06.012
[21] Mullan KA, Andersen A, Illing PT, Kwan P, Purcell AW, Mifsud NA. HLA-associated antiepileptic drug-induced cutaneous adverse reactions. HLA 2019:93:417–35. https://doi.org/10.1111/tan.13530